CurrentUnitedHealthcarePolicy MMP036.13

Capsule Endoscopy

This UnitedHealthcare Medicare Advantage medical policy governs coverage and medical necessity criteria for wireless capsule endoscopy (including esophageal and small bowel capsule) and wireless gastrointestinal motility monitoring (e.g., SmartPill) for Medicare Advantage members.

Policy Summary

PayerUnitedHealthcare

PolicyCapsule Endoscopy

Policy CodePolicy MMP036.13

Key ActionObtain prior authorization with documented indication and retention‑risk mitigation when requesting wireless capsule endoscopy or wireless motility capsule.

Change TypeNo material change

Effective DateApr 1, 2025

Next Review DateN/A

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3CPT codes listed

Small bowel & esophagusWCE indications

Gastroparesis & CICWMC covered uses

LCD/LCAMedicare references

89.6%Pooled completion rate

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Wireless Capsule Endoscopy (WCE) - Esophagus

Covered when ALL of the following are met

Esophageal WCE coverage: 1) Patient diagnosed with portal hypertension who requires immediate evaluation of esophageal varices; and 2) The esophageal capsule is performed in lieu of conventional endoscopy because the provider who would perform the endoscopy has determined that the patient's current medical condition prohibits a conventional endoscopy.

Performance for any other reason is not reasonable and necessary.

Wireless Capsule Endoscopy (WCE) - Small Bowel

Covered when ANY of the following groups are met

Small bowel WCE indications: A) Initial diagnosis of suspected Crohn's disease when conventional diagnostic tests (e.g., small bowel follow-through, and upper and lower endoscopy) provide no evidence of disease; OR B) Documented continuous blood loss and anemia secondary to obscure small-bowel bleeding, and any of the following: the site of bleeding could not be previously identified by colonoscopy or endoscopy; OR radiographic exams of the small bowel have failed to reveal a source; OR intraoperative enteroscopy is being considered.

Wireless Gastrointestinal Motility Monitoring System (WMC)

Covered when ALL of the following are met

WMC coverage: 1) Device is used by a gastroenterologist trained to use and interpret the results; and 2) Basic clinical investigations, including endoscopy, have failed to elucidate a diagnosis; and 3) It is used to evaluate suspected gastroparesis of any nature OR to evaluate colonic transit in patients with chronic idiopathic constipation lasting over 6 months.

Device is reasonable and necessary when these criteria are met.

Situations where WCE/WMC may be used

Evidence-informed coverage considerations and contexts where WCE or WMC may be indicated or limited:

WCE for esophagogastric varices: Wireless capsule endoscopy (including magnetically guided and detachable‑string variants) may detect and grade esophagogastric varices with high reported sensitivity and specificity in select studies, but current evidence does not support replacing esophagogastroduodenoscopy (EGD) as first‑line screening; WCE may be considered when EGD is contraindicated or refused.

Supported by Jiang et al. (2024) diagnostic accuracy findings and McCarty et al. (2017) systematic review noting insufficient sensitivity to replace EGD.

WCE for obscure GI bleeding (OGIB): Capsule endoscopy is recommended as an investigation for obscure gastrointestinal bleeding after negative EGD and colonoscopy and demonstrates variable diagnostic yield (reported range ~30%–88%) with pooled completion rates around 89.6% and pooled retention rates near 2%.

Supported by systematic reviews and guideline assessments.

Pretest imaging or patency assessment for retention risk: In patients with risk factors for capsule retention (e.g., Crohn's disease, history of small‑bowel obstruction or prior resection, prior abdominal/pelvic radiotherapy, chronic high‑dose NSAID use, known stricture or mass), obtain CT or MR enterography or perform a patency capsule prior to standard capsule endoscopy; patency capsule preferred if NSAID‑associated diaphragmatic strictures are suspected.

Clinical guideline context

Context and evidence supporting clinical use

Guideline and evidence context: ACG gives a conditional recommendation (low GRADE) that WMC may be an alternative to scintigraphic gastric emptying for evaluation of gastroparesis; AGA recommends meal‑based scintigraphy as the first‑line physiologic assessment and notes multiple measurement techniques exist; NICE advised uncertainty about clinical benefits and recommended use only with special arrangements for governance, consent, and audit or research.

Guidelines and assessments emphasize selective use and limited evidence quality.

Comparative diagnostic performance

Study performance findings

WMC vs GES performance: Lee et al. (2019) reported WMC detected delayed gastric emptying in a higher percentage of subjects than GES (34.6% vs 24.5%) with overall agreement ~75.7%. Sangnes et al. (2020) reported WMC sensitivity 0.92 and specificity 0.73 at a 300‑minute cutoff, and specificity increased to 0.83 at a 385‑minute cutoff without loss of sensitivity in that study.

Cutoff selection affects specificity and agreement between methods.

Wireless capsule endoscopy (WCE) is not indicated for colorectal cancer screening and is not reasonable and necessary for confirmation of lesions that are normally reachable by conventional upper or lower endoscopy (proximal to the ligament of Treitz or distal to the ileum). The policy also excludes WCE for patients with radiologically confirmed intestinal blockage, a significantly narrowed small bowel, or abnormal fistulas, and for use with non–FDA‑approved devices, implanted electromagnetic devices (e.g., pacemakers), or when performed by physicians not trained in endoscopy or in unsupervised independent diagnostic testing facilities.

Patients with a known bowel obstruction or other risk factors for retention (for example, prior small‑bowel resection, known stricture, or prior abdominal/pelvic radiotherapy) should not undergo capsule endoscopy because of the risk of capsule retention. When clinical concern for narrowing exists, radiographic small‑bowel imaging should be obtained to evaluate luminal patency prior to WCE; failure to evaluate retention risk factors or to obtain appropriate pre‑tests may affect coverage determinations.

Per U.S. Food and Drug Administration labeling for the SmartPill GI Monitoring System, the device is not for use in pediatric patients. This policy follows that restriction and does not authorize routine use of these ingestible motility capsules in pediatric populations.

Patency capsule testing is considered not reasonable and necessary by this policy. Peer‑reviewed literature supporting routine patency capsule use is limited and of poor quality, and case reports/series describe occasions where patency capsules caused obstruction requiring urgent intervention. Given these evidence limitations and reported risks, routine patency capsule testing is not supported.

Current evidence does not support replacing diagnostic esophagogastroduodenoscopy (EGD) with wireless capsule endoscopy as first‑line screening for esophageal varices. Systematic reviews report reasonable diagnostic accuracy in select studies but note heterogeneity and risk of bias; WCE may be considered only when EGD is contraindicated or refused, not as a routine replacement for EGD.

The National Institute for Health and Care Excellence (NICE) concluded that wireless capsule assessment of GI motility shows evidence of measuring function but that there is uncertainty about clinical benefit and patient selection. NICE recommends that use be limited to settings with special arrangements for clinical governance, consent, and audit or research, reflecting the need for cautious, controlled implementation rather than broad routine adoption.

Procedure and Diagnosis Coding

Covered CPT Codes / Procedure CodesCPT

91110	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus through ileum, with interpretation and report.
91111	Gastrointestinal tract imaging, intraluminal (e.g., capsule endoscopy), esophagus with interpretation and report.
91112	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report.
91299	Unlisted diagnostic gastroenterology procedure.

Associated ICD-10 Codes (examples listed)ICD-10

A18.32	Tuberculous enteritis.
C17.0	Malignant neoplasm of duodenum.
D50.0	Iron deficiency anemia secondary to blood loss (chronic).
K50.00	Crohn's disease of small intestine without complications.
K31.84	Gastroparesis.
K59.04	Chronic idiopathic constipation.
I85.00	Esophageal varices without bleeding.

Medicare LCD/LCA referencesmixed

LCD/LCA references

Multiple CMS LCDs and LCAs referenced for Wireless Capsule Endoscopy and Wireless Gastrointestinal Motility Monitoring Systems across MACs (e.g., L34081, L33774, L35089, L36427, L33455).

Coding guidance referencesmixed

No codes listed

Duration for chronic idiopathic constipation — clinical timeframe

Duration thresholdChronic idiopathic constipation must persist for greater than 6 months to meet WMC coverage consideration

Clinical contextWMC used to evaluate colonic transit in patients with chronic idiopathic constipation when basic investigations have failed to elucidate a diagnosis

Provider requirementDevice must be used by a gastroenterologist trained to use and interpret results

WMC gastric emptying cutoff — 300 minutes (ordinary); alternative 385 minutes discussed

Ordinary cutoff (WMC GET)300 minutes is the ordinary cutoff used to define delayed gastric emptying with WMC

Alternative cutoffA cutoff of 385 minutes has been reported in a study to increase specificity without loss of sensitivity

Evidence noteCutoff choice affects specificity and agreement with gastric emptying scintigraphy (GES) in comparative studies

WMC delayed gastric emptying cutoff — 300 minutes (ordinary); alternative cutoff 385 minutes reported to increase specificity

Definition of delayed GE (WMC)Delayed gastric emptying by WMC is typically defined as a gastric emptying time ≥ 300 minutes

Alternative specificity-enhancing cutoffRaising the cutoff to 385 minutes was reported to increase specificity (0.83) while maintaining sensitivity in Sangnes et al.

Clinical implicationSelection of cutoff influences test specificity and agreement with standard GES measurements

Prior Authorization, Documentation, and Billing Requirements

Prior Authorization

Prior Authorization Required When Indications Present

Prior Authorization is required when the indications for Wireless Capsule Endoscopy (WCE) or Wireless Motility Capsule (WMC) are present. Submit pre-authorization with documentation that the member meets the coverage criteria (e.g., evaluation for esophageal varices in portal hypertension, suspected Crohn's disease after negative conventional testing, obscure small-bowel bleeding after negative EGD/colonoscopy and radiographic exams, or suspected gastroparesis/colonic transit evaluation per WMC criteria).

Apply prior authorization per the member's plan benefits and any applicable LCD/LCA where required.
For Medicare Advantage members, follow plan or delegated prior authorization routing — if a delegate manages utilization, follow the delegate's PA process.

Documentation Required

Risk‑Factor Evaluation for Capsule Retention

Evaluate and document risk factors for capsule retention before performing capsule endoscopy. Assess for Crohn's disease, history of small-bowel obstruction, prior small-bowel resection, prior abdominal or pelvic radiotherapy, chronic high‑dose NSAID use, known strictures or masses, and symptoms concerning for obstruction.

If any risk factors are present or clinical concern for obstruction exists, obtain one or more of: CT or MR enterography (preferred) or patency capsule testing or other appropriate imaging prior to standard capsule administration.
Document rationale for chosen pretest(s) and any results that confirm patency or exclude obstruction.

Note

Prior Diagnostic Steps

Before proceeding with capsule testing, perform and document basic diagnostic steps: review prior conventional endoscopy (EGD and colonoscopy) and relevant radiographic exams (eg, SBFT, CT/MR enterography). For obscure GI bleeding, capsule endoscopy is generally considered after negative EGD and colonoscopy and when radiographic exams have failed to identify a source.

For inpatient overt bleeding, perform capsule endoscopy within 48 hours when possible to maximize diagnostic yield.
For suspected Crohn's disease, consider capsule endoscopy when conventional tests (including upper and lower endoscopy and small bowel radiography) do not provide a diagnosis.

Denial Risk

Patency Capsule Testing — Selective Use and Risks

Do not use patency capsule testing routinely; it is considered not reasonable and necessary as a blanket requirement because evidence is limited and the patency capsule itself can cause obstruction in rare cases. Use patency capsule selectively when cross-sectional imaging may miss NSAID‑associated diaphragmatic strictures or when concerns remain despite negative CT/MR enterography.

When patency capsule is used, document the clinical justification and inform the member of potential risks (including rare obstruction).
If CT or MR enterography is performed and shows no obstructive lesion but clinical concern persists (eg, Crohn's disease), document why patency testing was or was not performed.

Definitions

Wireless Capsule Endoscopy (WCE) definition

Basic definitionAn ingestible disposable capsule containing a light source, miniature color video camera, battery, antenna, and transmitter that records images of the GI mucosa transmitted to an external data recorder for physician review

FunctionPropelled naturally through the GI tract, records images while a patient-worn recorder captures transmitted data for later download and interpretation

Typical durationProcedure lasts ~5 minutes for esophageal mucosa and ~8 hours for intestinal mucosa

Wireless Gastrointestinal Motility Monitoring System (WMC / SmartPill) definition

Basic definitionAn ingestible capsule (eg, SmartPill) that records pH, temperature, and pressure to estimate regional and whole‑gut transit times and assess gastrointestinal motility

Indications (FDA)FDA-cleared to evaluate suspected delayed gastric emptying and to evaluate colonic transit time in chronic idiopathic constipation

Data outputProvides regional transit times (GET, SBTT, CTT, WGTT) and pressure patterns transmitted to a patient-worn receiver for analysis

Patency capsule definition — dissolvable test capsule to verify small-bowel patency

DefinitionA dissolvable test capsule used to verify small‑bowel patency prior to video capsule endoscopy in patients at risk for intestinal strictures or capsule retention

Use considerationASGE/ACG recommend patency capsule or CT/MR enterography before standard capsule administration when retention risk factors are present; patency capsule preferred for suspected NSAID‑associated diaphragmatic strictures

Safety notePatency capsule testing has been reported to cause obstruction in some cases and its routine use is debated in evidence summaries

WMC GET — definition and ordinary cutoff values

DefinitionWMC GET is the gastric emptying time measured by the wireless motility capsule and is used to identify delayed gastric emptying (gastroparesis)

Ordinary cutoffThe commonly used threshold for delayed gastric emptying by WMC is 300 minutes

Alternative cutoff reportedAn alternative cutoff of 385 minutes has been reported to increase specificity without reducing sensitivity in a comparative study

Gastric emptying time (GET) — definition

DefinitionGastric emptying time (GET) is the time measured by the system indicating gastric transit/emptying used to evaluate suspected gastroparesis

Clinical applicationGET identifies delayed gastric emptying implicated in idiopathic and diabetic gastroparesis and functional dyspepsia

Measurement sourceGET can be obtained by WMC or by gastric emptying scintigraphy (GES); comparative studies report variable agreement

Colonic transit time (CTT) — definition

DefinitionColonic transit time (CTT) is the measurement of transit through the colon used to evaluate colonic transit in patients with chronic constipation

Clinical useCTT aids in differentiating slow‑transit versus normal‑transit constipation and can be measured directly or inferred from combined small/large bowel measures when needed

WMC capabilityWMC (SmartPill) measures colonic transit time as part of its regional and whole gut transit time outputs

OpenPayer

Capsule Endoscopy

Coverage and Medical Necessity Criteria

Procedure and Diagnosis Coding

Prior Authorization, Documentation, and Billing Requirements

Background and Overview

Definitions